Farms.com Home   Ag Industry News

Monsanto won’t give up on Syngenta

CEO remains optimistic a deal will happen

By Diego Flammini, Farms.com

Despite two rejected bids by Syngenta, Monsanto’s CEO Hugh Grant remains confident that a deal to acquire the Swiss company is still a possibility.

In an interview with the Wall Street Journal, Grant said he would be “putting energy into putting this over the line.”

Grant said he’s had Syngenta on his radar since 2011, but not being able to secure a deal with them could be a black eye.

A merger between the two companies would create a titan in the agricultural industry with sales estimated to exceed $31 billion. The merger could also require Syngenta to sell off the seed business.

A merger that Grant estimates could take several months to finalize. Should no deal come to pass, Monsanto will look elsewhere to expand its business.

“We’ll figure out another way of doing that,” Grant told the Wall Street Journal. “This isn’t one where you fold up the tent and go back to how things were.”

Monsanto’s desire to purchase Syngenta started back in May when they tabled a $45 billion bid for the Swiss company that was met with rejection.

Another $45 billion offer in June came with a $2 billion contingency fee if regulators didn’t clear the deal. That offer too, was rejected.

“We have unanimously concluded that the proposal significantly undervalued Syngenta’s prospects but as well really underestimated the huge execution risk of this transaction,” said Chairman of Syngenta’s Board of Directors Michel Demaré in a video.

Tell us your thoughts on Monsanto’s push to acquire Syngenta.


Trending Video

Porcine Rotaviruses Explained - Dr. Anastasia Vlasova

Video: Porcine Rotaviruses Explained - Dr. Anastasia Vlasova

In this episode of The Swine it Podcast Show Canada, Dr. Anastasia Vlasova from The Ohio State University breaks down what rotaviruses are, how they affect pigs, and why they matter for swine health and productivity. She discusses virus diversity, transmission pathways, challenges in prevention, and how new vaccine technologies and diagnostic tools can shape the future of control strategies. Listen now on all major platforms!